January 2021 in “HAMDAN MEDICAL JOURNAL” This study reports that finasteride can effectively treat androgenic alopecia and may reduce prostate cancer risk by 25% in men with risk factors.
1 citations
,
September 2020 in “Pediatric Dermatology” In this case report, two adolescents developed androgenetic alopecia after treatment with anastrozole for idiopathic short stature, suggesting this potential side effect should be considered in pediatric patients using aromatase inhibitors.
July 2020 in “Journal of the American Academy of Dermatology” This analysis found that spironolactone use is not associated with an increased risk of breast cancer recurrence in female survivors.
1 citations
,
April 2020 in “Journal of The American Academy of Dermatology” This article discusses the approval status of 5α-reductase inhibitors for androgenetic alopecia, noting finasteride is FDA-approved for certain men while dutasteride is not approved in the US for this condition; it reports no new results.
27 citations
,
March 2017 in “Current Clinical Pharmacology” In this review, the authors discuss the pharmacology of dutasteride and compare its efficacy to finasteride for treating androgenetic alopecia, highlighting dutasteride's effectiveness demonstrated in several clinical trials.
February 2017 in “Vestnik dermatologii i venerologii” This review examines the molecular mechanisms and current treatment options for androgenetic alopecia, highlighting potential future therapies but providing no new experimental findings.
9 citations
,
January 2017 in “Farmacia” This review discusses the safety of finasteride for male androgenic alopecia and benign prostatic hyperplasia, concluding it remains a viable option due to synergistic effects with other treatments and predictive measures for side effect risk.
1 citations
,
September 2016 in “Actas Dermo-Sifiliográficas” 5-alpha reductase inhibitors may cause sexual side effects, breast complications, and other health risks in men with hair loss.
February 2012 in “Community oncology” Finasteride for hair loss may increase the risk of certain cancers and has side effects; better regulation and education on its use are needed.
16 citations
,
March 2011 in “Dermatologic Therapy” This study suggests that genetic variants in the androgen receptor gene may predict which postmenopausal women with hair loss respond to finasteride therapy.
9 citations
,
September 2010 in “Dermatologic Therapy” This article concludes that finasteride is a safe treatment for androgenetic alopecia and does not increase the risk of high-grade prostate cancer, despite past concerns from the Prostate Cancer Prevention Trial.
100 citations
,
April 2010 in “Expert Opinion on Pharmacotherapy” This article reviews existing treatments for male-pattern hair loss, noting that while they can slow progression, they generally achieve only partial hair regrowth.
33 citations
,
January 2009 in “Journal of Cutaneous and Aesthetic Surgery” This study found no clear evidence that finasteride negatively affects erectile function, though it does cause a reduction in ejaculatory volume and has potential implications for prostate cancer risk.
14 citations
,
April 2006 in “Expert Review of Dermatology” This review discusses therapeutic options for androgenetic alopecia, noting that while antiandrogen treatments prevent further hair loss and promote some regrowth, dramatic results are rare.
10 citations
,
October 2000 in “PubMed” This review discusses the diagnosis and treatment of androgenetic alopecia, emphasizing the importance of realistic patient expectations due to the psychosocial impact of hair loss, and reports no new clinical results.
2 citations
,
October 1998 in “Family Practice” New oral treatment, finasteride, effectively and safely treats common hair loss.
January 1998 in “NEJM Journal Watch” The abstract reports no new clinical results; it describes finasteride’s mechanism of action in androgenetic alopecia and mentions unpublished trial results by the manufacturer and investigators.
12 citations
,
May 1995 in “Australasian Journal of Dermatology” This review reports that while anti-androgen therapy can improve hair loss in up to 50% of women with androgenetic alopecia, it typically only slows the rate of loss rather than promoting new growth.
